JPS6416799A - H-pth (1-34) composition and its preparation - Google Patents
H-pth (1-34) composition and its preparationInfo
- Publication number
- JPS6416799A JPS6416799A JP62173549A JP17354987A JPS6416799A JP S6416799 A JPS6416799 A JP S6416799A JP 62173549 A JP62173549 A JP 62173549A JP 17354987 A JP17354987 A JP 17354987A JP S6416799 A JPS6416799 A JP S6416799A
- Authority
- JP
- Japan
- Prior art keywords
- organic acid
- peptide
- pth
- salt
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
PURPOSE:To obtain the title stabilized composition of increased thermal stability, by evaporating off the organic acid from the salt of human parathyroid hormone peptide (1-34) with a volatile organic acid as much as possible, then freeze-drying an aqueous solution of the hormone peptide in a tartaric acid aqueous solution of a specific concentration. CONSTITUTION:A volatile organic acid salt of human parathyroid hormone (h-PTH) peptide (1-34) of the formula is synthesized by the solid phase method and purified by chromatography or the like. Then, the volatile organic acid is removed from the salt as much as possible and the remaining peptide is dissolved in such a tartaric acid aqueous solution as the amount of tartaric acid ranges from 1.8 to 25wt.% based on the total amount and the solution is freeze-dried to give the subject stabilized h-PTH (1-34) composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62173549A JP2505812B2 (en) | 1987-07-10 | 1987-07-10 | Freeze-dried composition of h-PTH (1-34) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62173549A JP2505812B2 (en) | 1987-07-10 | 1987-07-10 | Freeze-dried composition of h-PTH (1-34) |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6416799A true JPS6416799A (en) | 1989-01-20 |
JP2505812B2 JP2505812B2 (en) | 1996-06-12 |
Family
ID=15962594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62173549A Expired - Lifetime JP2505812B2 (en) | 1987-07-10 | 1987-07-10 | Freeze-dried composition of h-PTH (1-34) |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2505812B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029337A1 (en) * | 1997-12-09 | 1999-06-17 | Eli Lilly And Company | Stabilized teriparatide solutions |
WO2002002136A1 (en) * | 2000-06-30 | 2002-01-10 | Suntory Limited | Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
EP1623723A3 (en) * | 1998-05-22 | 2006-05-10 | Dainippon Sumitomo Pharma Co., Ltd. | Stable gene formulations |
WO2011030774A1 (en) | 2009-09-09 | 2011-03-17 | 旭化成ファーマ株式会社 | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units |
WO2011062073A1 (en) | 2009-11-18 | 2011-05-26 | 旭化成ファーマ株式会社 | Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis |
WO2012169435A1 (en) | 2011-06-07 | 2012-12-13 | 旭化成ファーマ株式会社 | Freeze-dried preparation containing high-purity pth and method for producing same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1303100C (en) * | 2005-04-28 | 2007-03-07 | 华东理工大学 | Method for preliminary purification of recombinant human parathormone fusion protein by thermo osmosis shock technology |
-
1987
- 1987-07-10 JP JP62173549A patent/JP2505812B2/en not_active Expired - Lifetime
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550434B2 (en) | 1997-12-09 | 2009-06-23 | Eli Lilly And Company | Stabilized teriparatide solutions |
EP0920873A3 (en) * | 1997-12-09 | 1999-08-04 | Eli Lilly And Company | Stabilized teriparatide solutions |
WO1999029337A1 (en) * | 1997-12-09 | 1999-06-17 | Eli Lilly And Company | Stabilized teriparatide solutions |
EP1417972A1 (en) * | 1997-12-09 | 2004-05-12 | Eli Lilly & Company | Stabilized teriparatide solutions |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
EP1623723A3 (en) * | 1998-05-22 | 2006-05-10 | Dainippon Sumitomo Pharma Co., Ltd. | Stable gene formulations |
US7087248B2 (en) | 2000-06-30 | 2006-08-08 | Daiichi Asubio Pharma Co., Ltd. | Pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration comprising the component |
WO2002002136A1 (en) * | 2000-06-30 | 2002-01-10 | Suntory Limited | Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
EP2682125A1 (en) | 2009-09-09 | 2014-01-08 | Asahi Kasei Pharma Corporation | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 200 units |
WO2011030774A1 (en) | 2009-09-09 | 2011-03-17 | 旭化成ファーマ株式会社 | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units |
KR20210040171A (en) | 2009-09-09 | 2021-04-12 | 아사히 가세이 파마 가부시키가이샤 | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units |
KR20190095552A (en) | 2009-09-09 | 2019-08-14 | 아사히 가세이 파마 가부시키가이샤 | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units |
EP2682124A1 (en) | 2009-09-09 | 2014-01-08 | Asahi Kasei Pharma Corporation | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units |
KR20120116901A (en) | 2009-11-18 | 2012-10-23 | 아사히 가세이 파마 가부시키가이샤 | Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans |
WO2011062073A1 (en) | 2009-11-18 | 2011-05-26 | 旭化成ファーマ株式会社 | Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis |
EP3020409A1 (en) | 2011-06-07 | 2016-05-18 | Asahi Kasei Pharma Corporation | Freeze-dried preparation containing high-purity pth and method for producing same |
KR20160068987A (en) | 2011-06-07 | 2016-06-15 | 아사히 가세이 파마 가부시키가이샤 | Freeze-dried preparation containing high-purity pth and method for producing same |
EP3170493A1 (en) | 2011-06-07 | 2017-05-24 | Asahi Kasei Pharma Corporation | Freeze-dried preparation containing high-purity pth and method for producing same |
US10011643B2 (en) | 2011-06-07 | 2018-07-03 | Asahi Kasei Pharma Corporation | Freeze-dried preparation containing high-purity PTH and method for producing same |
WO2012169435A1 (en) | 2011-06-07 | 2012-12-13 | 旭化成ファーマ株式会社 | Freeze-dried preparation containing high-purity pth and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
JP2505812B2 (en) | 1996-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT78711A (en) | NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF | |
EP0215658A3 (en) | Improved formulation for recombinant beta-interferon processes for recovery and stabilization of beta-interferon and the use thereof | |
DK262683D0 (en) | DYNORPHINAMIDE ANALOGS | |
FI910286A0 (en) | ANALOGER AV HUMANT INSULIN OCH PREPARAT INNEHAOLLANDE DESSA. | |
JPS54147916A (en) | Preparation of urokinase injection | |
JPS559023A (en) | Production of dopa preparation in high concentration | |
SG46307A1 (en) | New pyrazine derivatives the preparation and use thereof | |
JPS6416799A (en) | H-pth (1-34) composition and its preparation | |
IT1241153B (en) | METHOD FOR PREPARING STABLE BITUMEN-POLYMER MIXTURES | |
ATE67406T1 (en) | PREPARATION FOR INJECTION CONTAINING NICORANDIL. | |
DE3676640D1 (en) | PRAZOSINE-PIRBUTEROL MIXTURE FOR BRONCH DILATATION. | |
KR840002657A (en) | Process for preparing interferon composition | |
DE69217686D1 (en) | Pharmaceutical composition of stabilized [Leu 13] motilin pod | |
JPS51125790A (en) | Carrier for fixing of biologically active substances | |
PT101007A (en) | ICRF-187 lyophilized and stably prepared and its use and ICRF-187 lyophilized preparation process | |
JPS52108088A (en) | Preparation of monohydroxycarboxylic acid using microbials | |
JPS57169425A (en) | Composition and method for preventing adsorption of secretin | |
HU911358D0 (en) | Grf analogues | |
JPS5283411A (en) | Preparation of 3,3-dimethyl-4-pentenoic acid and its derivatives | |
JPS53112815A (en) | Preparation of derivative of aliphatic isothiocyanic acid having basic substituent | |
JPS53113033A (en) | Antihyperlipemics | |
JPS5498306A (en) | Preparation of human blood-plasma cholinesterase | |
JPS57189662A (en) | Improvement of sweeteness of thaumatin | |
JPS5423634A (en) | Preparation of quinophthalone compounds | |
JPS5365867A (en) | Preparation of chenodeoxycholic acid crystal |